Role of Aprotinin in Glucagon Degradation, Measurement by Radioimmunoactive Method (RIA) I125

University Hospital, Gentofte, Copenhagen5 enrolled

Overview

The aim of the study was to investigate the role of the Trasylol in glucagon prevention in degradation using radioimmunoactive method with I125. Additionally different incubation time was introduced in human plasma samples after oral glucose stimulation, also in fasted and hypoglycemia blood samples from patients' type 2 diabetes. Since, the structure and the techniques for the glucagon measurement are well described nowadays.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Hyperglucagonemia

Interventions

Fasting glycemiaOTHER

no intervention

HypoglycemiaOTHER

Insulin induced hypoglycemia

Eligibility

Sex: MALEMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Caucasians 18 years or older with Type 2 diabetes (WHO criteria) Exclusion Criteria: * HbA1c \>9 % * Liver disease (ALAT/ASAT \>2 x upper normal limit) * Diabetic nephropathy (s-creatinine \>130 µM or albuminuria) * Proliferative diabetic retinopathy (anamnestic) * Severe arteriosclerosis or heart failure (NYHA group III og IV) * Anemia * treatment with medication not applicable to pause for 12 hours * pregnancy or lactation * Fasting plasma glucose \>15 mM on screening day.

Locations (1)

Gentofte Hospital

Hellerup, Denmark

Outcomes

Primary Outcomes

Change in plasma glucagon values measured with c-terminal specific "micro-protocol" RIA4305: 350µl of plasma (duplicate sample).

Time frame: 120 min

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.